KAFTRIO 75 mg/50 mg/100 mg, granules in a sachet 28 sachets
Active ingredients: Ivacaftor, Tezacaftor, Elexacaftor
Commercialized according to BDPMDispensing in France: Prescription only
Granules28 sachetsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- KAFTRIO 75 mg/50 mg/100 mg, granulés en sachet
- Pharmaceutical form
- granulés
- Route of administration
- orale
- Presentation description
- 28 (4 x7) sachet(s) BoPET : polyéthylène téréphtalate biaxialement orienté polyéthylène aluminium
- Marketing authorisation holder
- VERTEX PHARMACEUTICALS (IRELAND)
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 15 Feb 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66594621CIP73028035CIP133400930280355Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ÉLEXACAFTORgranulés | 100 mg · un sachet | SA |
| TEZACAFTORgranulés | 50 mg · un sachet | SA |
| IVACAFTORgranulés | 75 mg · un sachet | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.